长期注射卡博特韦/利匹韦林治疗未抑制病毒载量的HIV患者的实际经验。

IF 3.5 3区医学 Q2 VIROLOGY

Viruses-Basel Pub Date : 2025-09-17 DOI:10.3390/v17091254

Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio

{"title":"长期注射卡博特韦/利匹韦林治疗未抑制病毒载量的HIV患者的实际经验。","authors":"Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio","doi":"10.3390/v17091254","DOIUrl":null,"url":null,"abstract":"Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed. However, growing real-world evidence highlights its potential role in more complex viremic populations traditionally considered ineligible. We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events.","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 9","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474475/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load.\",\"authors\":\"Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio\",\"doi\":\"10.3390/v17091254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed. However, growing real-world evidence highlights its potential role in more complex viremic populations traditionally considered ineligible. We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events.\",\"PeriodicalId\":49328,\"journal\":{\"name\":\"Viruses-Basel\",\"volume\":\"17 9\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474475/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Viruses-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/v17091254\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/v17091254","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

长效注射卡波特韦/利匹韦林（CAB/RPV-LA）目前被批准用于病毒学抑制的HIV （PWH）患者的维持治疗。然而，越来越多的现实证据强调了它在传统上被认为不合格的更复杂的病毒种群中的潜在作用。我们提出了在意大利两个三级中心治疗的8例PWH病例系列，所有患者都面临持续性病毒血症、依从性困难、吸收不良综合征或心理社会障碍。在切换到CAB/RPV-LA后，尽管临床特征和基线病毒学状态不同，但所有患者都实现并维持了病毒学抑制，表现出更好的依从性，并且没有发生严重的不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load.

Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed. However, growing real-world evidence highlights its potential role in more complex viremic populations traditionally considered ineligible. We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Viruses-Basel VIROLOGY-

CiteScore

7.30

自引率

12.80%

发文量

2445

审稿时长

1 months

期刊介绍： Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the ''News and Views'' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.